The effect of COVID-19 vaccinations on menstrual cycle and serum anti-Mullerian hormone levels in reproductive age women

Simple item page
dc.contributor.authorHasdemir P.S.
dc.contributor.authorSenol Akar S.
dc.contributor.authorGoker A.
dc.contributor.authorKosova F.
dc.contributor.authorUcar D.
dc.contributor.authorOzalp Ates F.S.
dc.contributor.authorAkcali S.
dc.date.accessioned2024-07-22T08:03:29Z
dc.date.available2024-07-22T08:03:29Z
dc.date.issued2023
dc.description.abstractThe aim of this prospective cohort study was to investigate the effect of coronavirus disease 2019 (COVID-19) vaccinations on menstrual cycle and ovarian reserve in reproductive aged-women. Health care providers (n = 258) vaccinated with inactivated (CoronaVac) and mRNA based (Pfizer-BioNTech®) COVID-19 vaccines were included. All subjects completed a gynaecological and menstrual history questionnaire and Anti-Mullerian Hormone (AMH) levels were measured in serum samples collected before first vaccination and at 1st, 3rd, 6th and 9th months. The prevalence of new-onset menstrual dysregulation following vaccination was 20.6% and it was statistically significant compared to baseline (p = 0.001). Menstrual pattern turned back to normal in 59.6% of vaccinated women. Serum AMH levels gradually decreased until 6th month of follow-up compared to baseline (p < 0.001). A significant increase in serum AMH level was observed at 9th month of follow-up compared to 6th month follow-up levels (p < 0.001). The decrease in serum AMH level was statistically significant regardless of serum anti SARS-CoV-2 antibody levels, subgroups of age, occupation, menstrual dysregulation following vaccination and presence of gynaecological diseases. In conclusion, vaccination against SARS-CoV-2 causes a transient decrease on serum AMH levels and moderate irregularities in menstrual pattern increasing with age and is mostly reversible. © 2023 The British Fertility Society.
dc.identifier.DOI-ID10.1080/14647273.2023.2181710
dc.identifier.issn14647273
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12299
dc.language.isoEnglish
dc.publisherTaylor and Francis Ltd.
dc.subjectAdult
dc.subjectAnti-Mullerian Hormone
dc.subjectCOVID-19
dc.subjectCOVID-19 Vaccines
dc.subjectFemale
dc.subjectHumans
dc.subjectMenstrual Cycle
dc.subjectProspective Studies
dc.subjectSARS-CoV-2
dc.subjectcoronavac
dc.subjectmessenger RNA
dc.subjectMuellerian inhibiting factor
dc.subjectSARS-CoV-2 antibody
dc.subjecttozinameran
dc.subjectcoronavac
dc.subjectSARS-CoV-2 vaccine
dc.subjectadult
dc.subjectArticle
dc.subjectcohort analysis
dc.subjectcontrolled study
dc.subjectcoronavirus disease 2019
dc.subjectendometriosis
dc.subjectfemale
dc.subjectgene expression
dc.subjectgynecologic disease
dc.subjecthealth care personnel
dc.subjecthuman
dc.subjecthuman tissue
dc.subjectinfertility
dc.subjectleiomyoma
dc.subjectmajor clinical study
dc.subjectmenstrual cycle
dc.subjectmenstrual irregularity
dc.subjectnonhuman
dc.subjectovarian reserve
dc.subjectovariectomy
dc.subjectovary polycystic disease
dc.subjectpolyp
dc.subjectprospective study
dc.subjectprotein blood level
dc.subjectquestionnaire
dc.subjectSevere acute respiratory syndrome coronavirus 2
dc.subjectuterine cervix dysplasia
dc.subjectvaccination
dc.subjectcoronavirus disease 2019
dc.subjectmenstrual cycle
dc.titleThe effect of COVID-19 vaccinations on menstrual cycle and serum anti-Mullerian hormone levels in reproductive age women
dc.typeArticle

Files

Collections

Scopus Koleksiyonu